Literature DB >> 35580686

IgG functionalized polymeric nanoparticles for oral insulin administration.

J G B De Marchi1, R Cé2, G Onzi3, A C S Alves2, N Santarém4, A Cordeiro da Silva5, A R Pohlmann2, S S Guterres3, A J Ribeiro6.   

Abstract

The oral route is the best way to administer a drug; however, fitting peptide drugs in this route is a major challenge. In insulin cases, less than 0.5% of the administered dose achieves systemic circulation. Oral delivery by nanoparticles can increase insulin permeability across the intestinal epithelium while maintaining its structure and activity until release in the gut. This system can be improved to increase permeability across intestinal cells through active delivery. This study aimed to improve a nanoparticle formulation by promoting functionalization of its surface with immunoglobulin G to increase its absorption by intestinal epithelium. The characterization of formulations showed an adequate size and a good entrapment efficiency. Functionalized nanoparticles led to a desirable increase in insulin release time. Differential scanning calorimetry, infrared spectroscopy and paper chromatography proved the interactions of nanoparticle components. With immunoglobulin G, the nanoparticle size was slightly increased, which did not show aggregate formation. The developed functionalized nanoparticle formulation proved to be adequate to carry insulin and potentially increase its internalization by epithelial gut cells, being a promising alternative to the existing formulations for orally administered low-absorption peptides.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Functionalization; Intestinal permeation; Nanoparticle; Oral delivery; Release profile

Mesh:

Substances:

Year:  2022        PMID: 35580686     DOI: 10.1016/j.ijpharm.2022.121829

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  1 in total

Review 1.  Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy.

Authors:  Chunkang Liu; Kunzhe Wu; Huan Gao; Jianyang Li; Xiaohua Xu
Journal:  Diabetes Metab Syndr Obes       Date:  2022-08-31       Impact factor: 3.249

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.